Parabilis Medicines, the developer of drugs and antibody-drug conjugates targeting historically undruggable protein targets and based on stabilized helical peptides or Helicons, has filed for an IPO.

Parabilis Medicines, Inc.’s IPO spotlights Helicon peptide cancer drugs like zolucatetide, plus Regeneron’s $125M backing & ...

Nirogacestat (Ogsiveo; Springworks Therapeutics) is a therapy used to treat desmoid tumors, rare but aggressive growths that ...

Parabilis is teeing up the latest high-profile stock issuance in a year when biotech IPOs are averaging more than $286 million in total proceeds.

Parabilis Medicines has filed for an initial public offering. The clinical-stage biopharmaceutical company said it applied to list its common stock on the Nasdaq Global Market under the ticker PBLS, ...